Cagrisema 5+5mg 10+10mg Compound 10 Vials Powder
Cagrisema 5+5mg 10+10mg Compound 10 Vials Powder

Cagrisema 5+5mg 10+10mg Compound 10 Vials Powder

CagriSema is a combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist, under clinical investigation for metabolic conditions. This product listing covers two powder presentations, 5+5 mg and 10+10 mg, supplied in 10-vial kits.
Send Inquiry

Product Overview

 

CagriSema is a combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist, under clinical investigation for metabolic conditions. This product listing covers two powder presentations, 5+5 mg and 10+10 mg, supplied in 10-vial kits.

 

Technical Specifications

 

Parameter

Specification

Product Name

CagriSema Compound

Listed Strengths

5+5 mg / 10+10 mg

Product Form

Powder

Pack Size

10 vials

Active Ingredients

Cagrilintide and semaglutide

 

Product Effects

 

Weight Management: CagriSema is being investigated for weight management, combining cagrilintide and semaglutide through complementary receptor pathways.

 

Blood Glucose Control: Clinical trials have evaluated its effects on HbA1c, with Phase II results showing greater improvement than cagrilintide alone.

 

Clinical Weight-Loss Results: A Phase II trial reported an average body-weight reduction of 15.6% after 32 weeks.

 

Clinical Development: CagriSema entered Phase III clinical trials in 2023 and remains investigational.

 

Composition and Strength

 

Dual-Component Composition
CagriSema combines cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist. The two components are listed together as a dual-component formulation.

 

Strength Notation
The available presentations are labeled 5+5 mg and 10+10 mg. Each strength notation represents the stated amounts of the two components. The product label and batch-specific specification identify the applicable quantity basis for each presentation.

 

Quality Documentation

 

Certificate of Analysis (CoA)
Each available batch-specific CoA identifies the product batch, analytical test items, test results and applicable specifications.

 

Product Specifications
Product specifications document the stated composition, labeled strength, physical form and packaging information for the listed product.

 

Analytical Test Reports
Available analytical reports present the test methods, measured results and corresponding laboratory information for the tests performed.

 

Batch Traceability
Product batch identifiers link the corresponding labels and quality documentation, supporting batch-level record verification.

 

Packaging and Product Identification

 

Pack Configuration
Each kit is listed as a 10-vial presentation. The supplied package should contain the specified number of vials corresponding to the ordered product and strength.

 

Vial Identification
Product labels identify the product name, strength notation and batch number, providing the basic information needed to distinguish different product presentations and batches.

 

Receiving Inspection
Upon receipt, check the vial count, label consistency, packaging integrity and batch identification against the order details and accompanying product documents.

 

Storage Conditions

Storage Temperature: Store lyophilized powder at −20°C.

Light and Moisture Protection: Keep the product sealed and protected from light and moisture.

Shelf Life: Refer to the expiry date and batch-specific stability documentation for the applicable shelf life.

 

Supply Information

 

Minimum Order Quantity (MOQ): 1 kit, with 10 vials per kit.

 

Lead Time: 6–10 business days, subject to confirmed order and applicable regulatory requirements.

 

Quality Documentation: Available documentation may include product specifications, batch-specific Certificate of Analysis (CoA), and analytical test reports, depending on the product and batch.

 

Payment Terms: Payment terms are confirmed in the formal quotation before any transaction.

 

Shipping Information: Shipping costs and estimated transit times depend on the destination, shipping method, and applicable import requirements.

 

Supplier Verification: Company registration details and the supplier's role as manufacturer or distributor are available for business verification where applicable.

 

Ordering Process

 

Product and Order Confirmation
Confirm the selected CagriSema presentation, 5+5 mg or 10+10 mg, the required quantity and destination.

 

Quotation and Payment
A formal quotation specifies the ordered products, quantities, unit prices, total amount, payment terms and applicable shipping charges.

 

Order Processing
Order processing begins after the order details and payment arrangements are confirmed. The estimated lead time is 6–10 business days, as stated in the supply terms.

 

Shipment Arrangement
Shipping arrangements are coordinated according to the destination, applicable import requirements and agreed shipping method. Required commercial and shipping documents are prepared for the order.

 

Delivery and Order Follow-up
Available shipment tracking information is provided where supported by the shipping method. Order references are retained to support delivery inquiries and post-shipment communication.

 

Customer Feedback

1
2
3
4
4e1ca48d850dacc17be09ad63bf95b48
6

 

Our Factory

 

product-800-1125

product-800-431

 

Delivery And Transportation

 

jpg

product-800-392

 

FAQ

 

Q: What is the difference between CagriSema and semaglutide alone?

A: CagriSema combines cagrilintide, an amylin and calcitonin receptor agonist, with semaglutide, a GLP-1 receptor agonist. Semaglutide alone acts on the GLP-1 receptor, whereas CagriSema is being investigated as a dual-pathway combination.

Q: Is CagriSema being developed for obesity or type 2 diabetes?

A: CagriSema has been investigated for both weight management and type 2 diabetes. Clinical research has assessed body-weight changes and HbA1c, a marker of long-term blood glucose control.

Q: How does CagriSema differ from tirzepatide?

A: CagriSema combines cagrilintide and semaglutide, targeting amylin/calcitonin and GLP-1 receptor pathways. Tirzepatide acts as a dual GIP and GLP-1 receptor agonist. Their mechanisms and clinical trial results are different, so cross-trial weight-loss figures should not be treated as direct evidence of superiority.

Q: What should research buyers consider when sourcing CagriSema?

A: Research buyers should assess product identity, labeled composition, batch documentation, supplier traceability and applicable legal requirements for their intended research setting. Procurement specifications should match the requirements of the receiving institution and the relevant jurisdiction.

Q: Can CagriSema be used in human research or clinical treatment?

A: Use depends on the study protocol, applicable regulations and the product's authorization status. CagriSema is investigational and should not be represented as an approved treatment or used for clinical treatment outside applicable legal and ethical requirements.

Q: How should buyers compare CagriSema suppliers?

A: Compare the consistency of product specifications, batch-level documentation, supplier business credentials, shipping documentation and the supplier's ability to support the intended lawful research or procurement use. Price alone does not establish product identity or suitability.

Hot Tags: cagrisema 5+5mg 10+10mg compound 10 vials powder, China cagrisema 5+5mg 10+10mg compound 10 vials powder suppliers, factory, Cagrisema 5mg 5mg, Cagritirze 5 5mg, Cagritirze peptide, Mazdutide dosage, Retatrutide Cost 5mg 10mg 15mg 30mg 10 Vials, tirzepatide online

Looking for High-qualityWeight Loss Peptides?

With reliable stock, fast bulk delivery, custom packaging and OEM/ODM services,
we aim to be your trusted partner for peptide raw materials.

Send Inquiry